Financial Performance - The company reported a net profit margin of 12% for the fiscal year 2023, reflecting improved operational efficiency and cost management[16]. - The company's operating revenue for 2023 reached ¥1,175,865,495.37, representing a 22.20% increase compared to ¥962,236,989.55 in 2022[21]. - Net profit attributable to shareholders for 2023 was ¥128,064,789.56, a significant increase of 68.93% from ¥75,162,301.76 in 2022[21]. - The net profit after deducting non-recurring gains and losses was ¥116,454,595.15, up 82.90% from ¥63,022,045.56 in the previous year[21]. - The net cash flow from operating activities for 2023 was ¥280,936,613.38, reflecting a 34.80% increase from ¥208,414,149.84 in 2022[21]. - Basic earnings per share for 2023 were ¥0.74, a 64.44% increase compared to ¥0.44 in 2022[21]. - Total assets at the end of 2023 amounted to ¥1,121,775,074.61, marking a 14.86% increase from ¥975,398,854.28 at the end of 2022[21]. - Net assets attributable to shareholders increased to ¥788,732,464.94, a rise of 15.14% from ¥683,770,207.38 in 2022[21]. - The company achieved a total revenue of CNY 1,175,865,495.37, representing a year-on-year growth of 22.20%[86]. - The net profit attributable to shareholders reached CNY 12,806,480, representing a significant increase of 68.93% compared to the previous year[86]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 20% for 2024, driven by new product launches and market expansion strategies[16]. - Market expansion efforts include opening 50 new stores across key cities, aiming for a 10% increase in market share by the end of 2024[16]. - The company is exploring potential mergers and acquisitions to enhance its product offerings and market share, with a budget of 500 million RMB allocated for this purpose[138]. - The company plans to expand its market presence by opening 50 new retail locations across major cities in China by the end of 2024[138]. - The company is actively pursuing new business models in collaboration with public hospitals and community health institutions to enhance its professional capabilities[50]. - The company aims to enhance its market share and in-store conversion rates by improving its sales channel layout and integrating online and offline retail networks[125]. Research and Development - The company is investing in R&D for new technologies, with an allocated budget of RMB 30 million for the development of smart eyewear products[16]. - The company is actively investing in research and development for new eyewear technologies, aiming to enhance product offerings and customer experience[149]. - New product development includes the introduction of smart eyewear, expected to contribute an additional 200 million RMB in revenue in 2024[138]. - R&D investment amounted to ¥4,669,387.17 in 2023, representing 0.40% of total revenue[101]. - The company has employed 15 R&D personnel in 2023, marking a significant increase from 0 in 2022[101]. Customer Engagement and Experience - The management highlighted a focus on enhancing customer experience through digital transformation initiatives, including an upgraded e-commerce platform[16]. - The company aims to increase its online sales contribution to 40% of total revenue by 2025, leveraging digital marketing strategies[16]. - The company has implemented a "Quality Improvement" initiative aimed at enhancing customer satisfaction, which is expected to improve retention rates by 10%[139]. - The company is exploring new strategies for market expansion, aiming to enhance its competitive position in the industry[148]. - The company has established partnerships with two major e-commerce platforms to enhance distribution and reach a broader audience[159]. Governance and Compliance - The company's governance structure has been strengthened, ensuring compliance with regulatory requirements and enhancing operational transparency[140]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced decision-making process[140]. - The company has maintained a strong financial position, with no instances of fund misappropriation by the controlling shareholder during the reporting period[140]. - The company has established a fair and transparent performance evaluation and incentive mechanism for directors and senior management, ensuring compliance with legal regulations[141]. - The company received an A grade (excellent) for its information disclosure work during the reporting period, as evaluated by the Shenzhen Stock Exchange[142]. Employee and Talent Management - The company has established a comprehensive training system for employees, including onboarding, skill enhancement, and core talent training, to improve overall employee capabilities[175]. - The company emphasizes a competitive and fair compensation system to attract and retain talent, with adjustments made to salary schemes for frontline business departments[174]. - The total number of employees at the end of the reporting period was 2,367, with 971 in the parent company and 1,396 in major subsidiaries[172]. - The company has 270 employees with a bachelor's degree or higher, representing about 11.4% of the total workforce[172]. - The company actively engages in school-enterprise cooperation to enhance talent cultivation in the optical industry[175]. Risks and Challenges - The company faces risks from macroeconomic fluctuations that could negatively impact consumer spending and overall performance[129]. - Intense market competition in the eyewear retail industry may hinder the company's ability to maintain or enhance its competitive advantages[130]. - The franchise business development is in its early stages, with uncertainties in conversion rates and procurement amounts, posing risks to expansion efforts[132]. - Human resource management risks exist as the company's growth is directly tied to the availability and quality of professional talent[134]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 6 per 10 shares to all shareholders, totaling approximately RMB 60 million based on the current number of shares[4]. - The company distributed cash dividends of RMB 3 per 10 shares (including tax) to all shareholders based on the total number of shares registered on the dividend distribution date[176]. - The company has a policy to ensure that cash dividends constitute at least 20% of the profit distribution when significant capital expenditures are planned[178]. - The cash dividend amount is derived from a distributable profit of RMB 200,357,750.78[178]. Sales and Revenue Channels - The online transaction total (GMV) was 207.50 million yuan, with corresponding operating revenue (excluding tax) of 183.92 million yuan, accounting for 15.64% of total revenue, up 44.68% year-on-year[60]. - Offline retail sales were CNY 991,941,676.07, which is 84.36% of total revenue, showing an 18.78% increase from the previous year[89]. - The company has established long-term partnerships with renowned suppliers such as Carl Zeiss and LVMH, ensuring product diversity and competitive pricing[84]. - The company has implemented a centralized procurement model, ensuring efficient supply chain management and inventory control[79]. Digital Transformation - The company is actively embracing digital transformation by enhancing its online membership system and utilizing social media platforms for brand promotion[59]. - The eyewear retail industry is experiencing a shift towards digital transformation, with new retail models enhancing the connection value of retail endpoints[46]. - The company has established official accounts on local life service platforms such as Douyin and Dazhongdianping to enhance customer engagement and service delivery[61].

证券研究报告 | 年报点评报告 2024 年 04 月 03 日 博士眼镜（300622.SZ） 数字化赋能长期发展，产品&渠道结构优化 公司发布 2023 年年报：2023 年实现收入 11.76 亿元（同比+22.2%），归母净利 润 1.28 亿元（同比+68.9%）；单 Q4 实现收入 2.70 亿元（同比+17.0%），归母 净利润 0.30 亿元（同比+11.6%）。Q4 计提商誉减值 530 万元，主要系轻加盟未达 业绩承诺目标，实际经营利润表现稳健，高毛利功能产品占比稳步提高，渠道、营 销体系持续丰富。 健全数字化零售体系，功能性产品增长亮眼。2023 年公司新设"数据运营部"、"用 户运营部"，深度挖掘和分析有效数据，优化售前售后服务管理模式，推动产品结 构升级。1）功能性产品：2023 年公司加强功能性产品的科普力度和营销推广活动， 功能性镜片销量稳中有进（同比+43.1%），其中离焦镜片/成人渐进镜片销量分别 同比+79.1%/+55.7%。2）自有品牌：2023 年自有品牌镜片销量占比 65.8%（销 量同比+6.0%）。 老店提质增效，新零售高速发展。公司完善线下销售网络并积极布局新 ...

盈利能力来看：23 年公司实现毛利率 63.07%/+1.23pct，销售费率 40.49%/- 2.4pct，管理费率 7.83%/-1.34pct，财务费率 0.40%/-0.59pct，实现净利率 11.2%/+3.53pct；2）存货周转率 2.58，应收账款周转率 20.81，相较于 22 年 均略有提升。 风险提示：加盟业务拓展不及预期，消费力疲软，竞争格局加剧 P/B 4.30 3.73 3.09 2.57 2.15 请阅读最后一页免责声明及信息披露 http://www.cindasc.com 2 百万元 利润表 单位 营业总收入 962 1176 1378 营业税金及附加 3 5 5 管理费用 88 92 103 财务费用 10 5 2 投资净收益 7 9 9 营业外收支 2 -3 0 所得税 18 32 41 少数股东损益 -1 4 5 | --- | --- | |-------|------------------| | 2025E | : 百万元 \n2026E | | 1612 | 1898 | | 615 | 730 | | 6 | 8 | | 629 | 734 | | 119 ...

证券代码：300622 证券简称：博士眼镜 公告编号：2024-029 博士眼镜连锁股份有限公司 关于 2021 年限制性股票与股票期权激励计划预留部分授予 股票期权第二个行权条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 博士眼镜连锁股份有限公司（以下简称"公司"）于 2024 年 4 月 1 日召开 第五届董事会第二次会议、第五届监事会第二次会议，分别审议通过了《关于 2021 年限制性股票与股票期权激励计划预留部分授予股票期权第二个行权条件 成就的议案》，公司 2021 年限制性股票与股票期权激励计划预留部分授予股票 期权第二个行权条件已成就。本次激励计划中预留部分授予股票期权符合可行权 的激励对象共 38 名，可行权的股票期权数量为 161,400 份，行权价格为 17.01 元/份（调整后）。现将相关内容公告如下： 一、公司 2021 年限制性股票与股票期权激励计划简述及已履行的相关审批 程序 （一）本次激励计划简述 1、公司《2021 年限制性股票与股票期权激励计划（草案）》（以下简称"《激 励计划》"、"本激励计划"）及其摘要已经 ...

证券代码：300622 证券简称：博士眼镜 公告编号：2024-033 总经理 LOUISA FAN 女士，副总经理 BING XIA 先生，董事夏伟奇先生，董 事会秘书丁芸洁女士，财务总监康海文先生，独立董事王伟先生（如遇特殊情况， 参会人员可能进行调整）。 三、投资者参加方式 投资者可于 2024 年 4 月 9 日（星期二） 15:00-17:00 通过网址 https://eseb.cn/1cZWyzDWUi4 或使用微信扫描下方小程序码即可进入参与互 动交流。投资者可于 2024 年 4 月 9 日前进行会前提问，公司将通过本次业绩说 明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。欢迎广大投资 者积极参与。 1 博士眼镜连锁股份有限公司 关于举行 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 博士眼镜连锁股份有限公司（以下简称"公司"）《2023 年年度报告》及其摘 要于 2024 年 4 月 3 日披露在巨潮资讯网（www.cninfo.com.cn），敬请投资者查 阅。为便于广大投资者更加全面深入 ...

博士眼镜连锁股份有限公司 审计报告 大华审字[2024]0011007834 号 大华会计师事务所 ( 特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 博士眼镜连锁股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-6 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-107 | 大华审字[2024] 0011007834 号审计报告 审 计 报 告 大华 ...

博士眼镜连锁股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字[2024]0011000609 号 大华会计师事务所 ( 特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 博士眼镜连锁股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项 说明 1-2 二、 博士眼镜连锁股份有限公司 2023 年度非经营 性资金占用及其他关联资金往来情况汇总表 1-4 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 大华核字[2024] 0011000609 号 博士眼镜连锁股份有限公司全体股东： 我们接受委托，依据《中国注册会计师执业 ...

博士眼镜连锁股份有限公司 2023 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下合称"企业内部控制规范体系"），结合博士眼镜连锁股份有限公司（以 下简称"本公司"或"公司"或"博士眼镜"）内部控制相关制度，在内部控制 日常监督和专项监督的基础上，对本公司截至 2023 年 12 月 31 日（内部控制评 价报告基准日）的内部控制有效性进行了自我评价。 三、内部控制评价工作依据及内部控制缺陷认定标准 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告系本公司董事会的责任；监事会对董事会 建立和实施内部控制进行监督；管理层负责组织领导企业内部控制的日常运行。 本公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在 任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整 性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上 ...

《公司章程》修正案 根据《公司法》《证券法》《上市公司章程指引》等有关法律法规的规 定，公司 2021 年限制性股票与股票期权激励计划预留部分授予股票期权第一个 行权期已届满，及公司 2021 年限制性股票与股票期权激励计划限制性股票回购 注销所涉公司变更注册资本事宜，经博士眼镜连锁股份有限公司（以下简称 "公司"）第五届董事会第二次会议决议，对《公司章程》做如下修订： | 原条款 | | | | | | | | | 修订后条款 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 第六条 公司注册资本为人民币（大 | | | | | | 第六条 | | | | 公司注册资本为人民币（大 | | | | | | 写）壹亿柒仟叁佰陆拾玖万壹仟叁佰 | | | | | | | | | 写）壹亿柒仟叁佰柒拾伍万伍仟玖佰 | | | | | | | 壹拾壹元（￥173,691,311 元），实收 | | | | | | | | 壹拾壹元（￥173,755,911 ...

博士眼镜连锁股份有限公司 2023 年度监事会工作报告 2023 年度博士眼镜连锁股份有限公司（以下简称"公司"）监事会严格按照 《公司法》《证券法》《公司章程》及《监事会议事规则》等相关规定，恪尽职 守，勤勉尽责地履行各项职责，认真出席历次监事会，列席董事会和股东大会， 依法检查公司财务，监督董事、高级管理人员履行职责的合法合规性，促进公司 规范化运作，切实维护了公司利益和全体股东的合法权益。现将 2023 年度监事 会主要工作情况报告如下： 一、报告期内监事会工作情况 公司监事会设立监事 3 名，其中职工代表监事 1 名，监事会的人数及人员 构成符合法律法规的要求。报告期内，监事会共召开监事会会议 6 次，会议的 召集、召开、议事、表决程序均符合《公司法》及《公司章程》等法律法规和 规范性文件的规定，全体监事无缺席会议的情况，对提交监事会审议的议案未 提出异议。会议具体情况如下： 1、2023 年 2 月 27 日，公司召开第四届监事会第十八次会议，审议通过了 《关于对外投资的议案》。 2、2023 年 4 月 25 日，公司召开第四届监事会第十九次会议，审议通过了 《关于<2022 年度监事会工作报告> ...